EQS-Adhoc: M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment

01.04.25 17:13 Uhr

Werte in diesem Artikel

Aktien

18.38 EUR -0.74 EUR -3.87 %

EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Investment/Miscellaneous
M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment

01-Apr-2025 / 17:13 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment

HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.

A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.

The company will provide further information in due course.
Contact:
Attila Strauss, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

End of Inside Information

01-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	M1 Kliniken AG
	Grünauer Straße 5
	12557 Berlin
	Germany
Phone:	+49 (0)30 347 47 44 14
Fax:	+49 (0)30 347 47 44 17
E-mail:	ir@m1-kliniken.de
Internet:	https://www.m1-kliniken.de
ISIN:	DE000A0STSQ8
WKN:	A0STSQ
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2110090